Amgen Racks Up Positive Phase III Data For Blincyto And Repatha
This article was originally published in The Pink Sheet Daily
Executive Summary
Company announces positive results from a confirmatory study of bispecific antibody Blincyto, on the heels of unveiling positive new data for PCSK9 inhibitor Repatha in statin-intolerant patients.
You may also be interested in...
Does Esperion's Plan For A Statin-Intolerant Claim Have A Shot?
Esperion says it is working with FDA to forge a new regulatory path for its cholesterol drug ETC-1002 in statin-intolerant patients – a population the agency has been very cautious about in the past.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.